4. Some Innovative Technologies For The Correction Of Valvular Heart Diseases. Review

Authors

  • I.Y. Sagatov JSC «A.N. Syzganov National Scientific Center for Surgery», Almaty, Kazakhstan
  • A.B. Kudaibergen JSC «A.N. Syzganov National Scientific Center for Surgery», Almaty, Kazakhstan
  • B.M. Momynov JSC «A.N. Syzganov National Scientific Center for Surgery», Almaty, Kazakhstan

Downloads

Abstract

Valve defects or congenital/acquired heart defects are damage to the valve and/or subvalvular structures, which leads to impaired hemodynamics and the development of heart failure. Asymptomatic valvular heart disease is present in 2.5% of the population; with age, this figure rises to 13%. In the absence of permanent treatment, lesions of the heart valves signifi-cantly reduce the quality and duration of life. The European Society of Cardiology (ESC) and the American Heart Association (AHA) regularly review the effectiveness of new surgical treatments and reflect their findings in international guidelines. Today, minimally invasive surgery is the most effective and safe way to treat patients with valvular heart disease. The article presents two new methods for the treatment of valvular heart disease. Transapical mitral valve repair on a beating heart with neochord implantation (TOP-MINI) is a new MVP option that has been approved for patients with severe mitral regurgitation due to prolapse of the leaflet (s) or chord (grades 2-4). The new procedure with the NeoChord DS1000 device results in a significant reduction in mitral regurgitation and in reverse remodeling of the left ventricle and left atrium after 6 months of follow-up. Also reviewed is Minimally Invasive Aortic Valve Replacement (MAVR), which has been shown to be beneficial in improving patient satisfaction by minimizing pain and earlier recovery. Sutureless valves are preferred over traditional aortic valve replacement (AVR) due to the reduced operation time and the need for blood transfusion. The Perceval valve (Sorin, Sallugia, Italy) is a self-expanding bovine pericardial prosthesis placed in a nitinol stent designed to facilitate aortic valve implantation. A systematic review and meta-analysis demonstrated that the early clinical and hemodynamic characteristics of the Perceval valve are satisfactory and comparable to those of conventional AVRs. This literature review was carried out in accordance with the PRISM statement. The databases searched in this review included Pubmed, Web of Science, Scopus and Cochrane databases for systematic reviews. Keywordsmitral valve, correction

Keywords

mitral valve, correction https://

References

  1. P. Bajona, W. E. Katz, R. C. Daly, K. J. Zehr, and G. Speziali, “Beating-heart, off-pump mitral valve repair by implantation of artificial chordae tendineae: An acute in vivo animal study,” J. Thorac. Cardiovasc. Surg. 137(1), 188–193 (2009)
  2. I. Bahar, A. Akgul, M. A. Ozatik, K. M. Vural, A. E. Demirbag, M. Boran, and O. Tasdemir, “Acute renal failure following open heart surgery: Risk factors and prognosis,” Perfusion 20(6), 317–322 (2005)
  3. R. Freeman, B. King, and M. H. Hambling, “Infective toring of infections by the NBT test,” Thorax 28(5), 617–621 (1973)
  4. M. F. Newman, J. P. Mathew, H. P. Grocott, G. B. Mackensen, T. Monk, K. A. Welsh-Bohmer, J. A. Blu-menthal, D. T. Laskowitz, and D. B. Mark, “Central nervous system injury associated with cardiac sur-gery,” Lancet 368(9536), 694–703 (2006)
  5. A. Iribarne, R. Easterwood, E. Y. H. Chan, J. Yang, L. Soni, M. J. Russo, C. R. Smith, and M. Argenziano, “The golden age of minimally invasive cardiothoracic surgery: Current and future perspectives,” Future Cardiol. 7(3), 333–346 (2011). 10. http://www.neochord.com/ for NeoChord DS1000
  6. T. Feldman, E. Foster, M. Qureshi, B. Whisenant, J. Williams, D. Glower, and L. Mauri, “TCT-788 the EVEREST II randomized controlled trial (RCT): Three year outcomes,” J. Am. Coll. Cardiol. 60(17), B229– B230 (2012). Medical Physics, Vol. 42, No. 1, Janu-ary 2015, 468. 12. http://www.abbottvascular.com/int/mitraclip. html#overview for MitraClip percutaneous mitral valve repair system. 13. http://www.mitralign.com/themitralignsystem for the mitralign system
  7. J. Harnek, J. G. Webb, K.-H. Kuck, C. Tschope, A. Vahanian, C. E. Buller, S. K. James, C. P. Ti-efenbacher, and G. W. Stone, “Transcatheter im-plantation of the MONARC coronary sinus device for mitral regurgitation: 1- year results from the EVOLUTION phase I study (clinical evaluation of the Edwards lifesciences percutaneous mitral annuloplasty system for the treatment of mitral regurgitation),” JACC: Cardiovasc. Interv. 4(1), 115–122 (2011)
  8. C. A. Linte, J. White, R. Eagleson, G. M. Guiraudon, and T. M. Peters, “Virtual and augmented medical imaging environments: Enabling technology for mini-mally invasive cardiac interventional guidance,” IEEE Rev. Biomed. Eng. 3, 25–47 (2010)
  9. G. M. Guiraudon, D. L. Jones, D. Bainbridge, and T. M. Peters, “Mitral valve implantation using off-pump closed beating intracardiac surgery: A feasibil-ity study,” Interact. Cardiovasc. Thorac. Surg. 6(5), 603–607 (2007)
  10. J. Ender and S. Sgouropoulou, “Value of transesoph-ageal echocardiography (TEE) guidance in minimally invasive mitral valve surgery,” Ann. Cardiothorac. Surg. 2(6), 796–802 (2013)
  11. Brown JM, O’Brien SM, Wu C, et al. Isolated aor-tic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Sur-geons National Database. J Thorac Cardiovasc Surg 2009;137:82-90
  12. Flameng W, Herregods MC, Hermans H, et al. Effect of sutureless implantation of the Perceval S aor-tic valve bioprosthesis on intraoperative and early postoperative outcomes. J Thorac Cardiovasc Surg 2011;142:1453-7
  13. Concistre G, Santarpino G, Pfeiffer S, et al. Two alternative sutureless strategies for aortic valve re-placement: a two-center experience. Innovations (Phila) 2013;8:253-7
  14. Lorusso R, Gelsomino S, Renzulli A.Sutureless aor-tic valve replacement: an alternative to transcath-eter aortic valve implantation? Curr Opin Cardiol 2013;28:158-63
  15. Martens S, Zierer A, Ploss A, et al. Sutureless Aortic Valve Replacement via Partial Sternotomy. Innova-tions (Phila) 2010;5:12-5
  16. Sadowski J, Kapelak B, Pfitzner R, et al. Suture-less aortic valve bioprothesis ‘3F/ATS Enable’--4.5 years of a single-centre experience. Kardiol Pol 2009;67:956-63
  17. Santarpino G, Pfeiffer S, Concistré G, et al. The Per-ceval S aortic valve has the potential of shortening surgical time: does it also result in improved outcome? Ann Thorac Surg 2013;96:77-81; discussion 81-2
  18. Cao C, Ang SC, Indraratna P, et al. Systematic re-view and meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. Ann Cardiothorac Surg 2013;2:10-23
  19. Vahanian A, Otto CM. Risk stratification of patients with aortic stenosis. Eur Heart J 2010;31:416-23
  20. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in pa-tients who cannot undergo surgery. N Engl J Med 2010;363:1597-607. SOME INNOVATIVE TECHNOLOGIES FOR THE CORRECTION OF VALVULAR HEART DISEASES. REVIEW

Published

2021-12-17

Issue

No. 4 (2021)

Section

Статьи